Biond Biologics

Company Overview

Snapshot

Founded in April 2016 by Tehila Ben Moshe and Ori Shilo, Biond Biologics operates with 11–50 employees. The company has raised $45 million across 4 funding rounds from 7 investors. In June 2026, Biond Biologics announced the appointment of Giovanni Selvaggi, MD, as Chief Medical Officer.

Business overview

Biond Biologics is a biotechnology company focused on developing immunotherapies and an intracellular drug delivery platform for cancer and autoimmune diseases. The company's core technology involves biologics that target novel immune evasion mechanisms, identified through in-house research using patient and tumor samples. Additionally, Biond Biologics is advancing an intracellular delivery platform designed to enable biologics, such as antibodies or enzymes, to target intracellular components previously considered undruggable. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In October 2025, Biond Biologics initiated a Phase 2 study for BND-22 in combination with anti-PD-1 therapy. This development signals continued progress in the company's clinical pipeline and its commitment to advancing novel immunotherapies, which could significantly impact the treatment landscape for cancer patients and validate its drug development strategy to investors.

Company Intelligence Q&A

What was a significant recent leadership appointment at Biond Biologics?

In June 2026, Biond Biologics appointed Giovanni Selvaggi, MD, as Chief Medical Officer (CMO). This strategic hire is expected to bolster the company's clinical development efforts for its immunotherapy pipeline.

What was the most recent funding event for Biond Biologics?

In June 2026, Biond Biologics closed an $8 million investment and collaboration with Guangzhou Sino-Israel Biotech Investment Fund (GIBF).

What clinical milestone did Biond Biologics achieve in October 2025?

In October 2025, Biond Biologics announced the initiation of a Phase 2 study for its investigational drug BND-22, which is being evaluated in combination with anti-PD-1 therapy for cancer treatment.

When did Biond Biologics announce the first patient dosing in the Phase 1 clinical trial for BND-22?

In April 2021, Biond Biologics announced the first patient had been dosed in the Phase 1 clinical trial for BND-22, a novel immune checkpoint inhibitor targeting the ILT2 receptor.

What strategic agreement did Biond Biologics enter into in January 2021?

In January 2021, Biond Biologics and Sanofi entered into a global licensing agreement for BND-22, a novel immune checkpoint inhibitor targeting the ILT2 receptor, indicating a significant partnership for the development and commercialization of this asset.